Viewing Study NCT03381664



Ignite Creation Date: 2024-05-06 @ 10:55 AM
Last Modification Date: 2024-10-26 @ 12:37 PM
Study NCT ID: NCT03381664
Status: COMPLETED
Last Update Posted: 2018-02-23
First Post: 2017-12-18

Brief Title: Study to Assess the Bioavailability Pharmacokinetics Safety and Tolerability of AVP-923 in Healthy Adult Participants
Sponsor: Avanir Pharmaceuticals
Organization: Avanir Pharmaceuticals

Study Overview

Official Title: A Phase 1 Randomized Single-Dose 3-Way Crossover Study to Compare the Relative Bioavailability Pharmacokinetics Safety and Tolerability of AVP-923 Dextromethorphan Hydrobromide and Quinidine Sulfate Capsules Administered in Applesauce or Via a Nasogastric Feeding Tube With Administration of a Capsule in Healthy Adult Subjects
Status: COMPLETED
Status Verified Date: 2018-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will be conducted to evaluate the relative bioavailability pharmacokinetics safety and tolerability of AVP-923 dextromethorphan hydrobromide DM and quinidine sulfate Q capsules when the contents of a capsule are administered in applesauce or via a nasogastric feeding tube compared with administration of a capsule in healthy fasting adult participants
Detailed Description: This is an open-label single-center randomized single-dose 3-treatment 3-period 6-sequence crossover study in healthy adult participants consisting of approximately 7 weeks of treatment The study population will be limited to extensive metabolizers of cytochrome P450 CYP 2D6

Approximately 18 participants will be randomly assigned to 1 of 6 sequences ABC ACB BAC BCA CAB CBA

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None